DAWN News and Press, Day One Biopharmaceuticals Inc. From 08/04/22

Day One Biopharmaceuticals press release ( NASDAQ: DAWN ): Q2 GAAP EPS of -$0.60. Cash, cash equivalents and short-term investments totaled $394.9 million on June 30, 2022. Based on current operating plan, management believes it has sufficient capital resources to fund ant...

Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected in the first quarter of 2023 Expanded development of tovorafenib with initiation of p...

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that man...

One of today's notable stocks on the rise is Day One Biopharmaceuticals Inc. (NGS:DAWN), up 144.6% to $17.17. In the past 52 weeks, Day One Biopharmaceuticals Inc. share prices are bracketed by a low of $5.44 and a high of $28.70 and is now at $17.17, 216% above that low price. Receive...

Day One Biopharmaceuticals Inc. (NGS:DAWN) is one of today's biggest movers, up 132.9% to $16.35. In the past 52 weeks, shares of Day One Biopharmaceuticals Inc. have traded between a low of $5.44 and a high of $28.70 and is now at $16.35, which is 201% above that low price. Receive IB...

SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced th...

Day One Biopharmaceuticals IPOed in May last year, raising $160m. Day One Biopharma's mission statement is to develop better pediatric cancer drugs. Lead candidate Tovorafenib posted strong early data from a Phase 2 trial in a common form of pediatric brain cancer with ORR of 64% ...

There's nothing like a good clinical trial readout to get the blood pumping for a biotechnology industry that has been under a lot of pressure. The tech-laden Nasdaq Composite index may be down more than 30% this year, but that didn't stop money from pouring into Day One Biopharmaceut...

Day One Biopharmaceuticals (NASDAQ:DAWN) has priced its upsized underwritten public offering of 10M shares of its common stock at $15.00/share for expected gross proceeds of $150.0M from prior $125M. All shares of common stock are being offered by Day One. Underwriters are granted a 30-d...

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announc...